{"url_path":"/sec/lixt/8-k/2026-07-02/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 Financial Statements and Exhibits**","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-02","source_url":"https://www.sec.gov/Archives/edgar/data/1335105/0001493152-26-031870-index.html","accession_number":"0001493152-26-031870","cik":"0001335105","ticker":"LIXT","issuer_name":"NOMAD POWER SOLUTIONS, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1335105/0001493152-26-031870-index.html","primary_entity_key":"0001335105","primary_entity_name":"LIXTE BIOTECHNOLOGY HOLDINGS, INC."},"word_count":353,"has_tables":true,"body_markdown":"**Item\n9.01 Financial Statements and Exhibits**\n\n \n\n(a)\nFinancial Statements of Businesses or Funds Acquired. As permitted by Item 9.01(a)(3) of Form 8-K, any financial statements required\nby this Item will be filed by amendment to this Report within 71 days following the date on which this Current Report on Form 8-K is\nrequired to be filed.\n\n \n\n(b)\nPro Forma Financial Information. As permitted by Item 9.01(b)(2) of Form 8-K, any financial statements required by this Item will be\nfiled by amendment to this Report within *71 days* following the date on which this Current\nReport on Form 8-K is required to be filed.\n\n \n\n(d)\nExhibits. The following exhibits are filed herewith.\n\n \n\n**Exhibit**\n\n**Number**\n\n \n**Description**\n\n2.1\n \n[Merger Agreement, dated as of June 11, 2026, by and among Lixte Biotechnology Holdings, Inc., NBD Merger Sub, Inc., and NOMAD Transportable Power Systems, Inc., (filed as Exhibit 2.1 to the Company’s Current Report on Form 8-K, filed on June 16, 2026, and incorporated herein by reference)*](https://www.sec.gov/Archives/edgar/data/1335105/000149315226028878/ex2-1.htm)\n\n2.2\n \n[Amendment No. 1 to Merger Agreement, dated as of June 30, 2026, by and among Lixte Biotechnology Holdings, Inc., NBD Merger Sub, Inc., and NOMAD Transportable Power Systems, Inc.*](ex2-2.htm)\n\n3.1\n \n[Certificate of Amendment of Certificate of Incorporation of Lixte Biotechnology Holdings, Inc.](ex3-1.htm)\n\n3.2\n \n[Amendment\nto Amended and Restated Bylaws](ex3-2.htm)\n\n3.3\n \n[Certificate of Designations of Preferences, Rights and Limitations of Series D Non-Voting Convertible Preferred Stock](ex3-3.htm)\n\n10.1\n \n[Registration Rights Agreement](ex10-1.htm)\n\n10.2\n \n[Stockholder\nSupport Agreement](ex10-2.htm)\n\n10.3\n \n[Form of Indemnification Agreement](ex10-3.htm)\n\n99.1\n \n[Press Release, dated July 2, 2026](ex99-1.htm)\n\n104\n \nCover\nPage Interactive Data File (embedded within the inline XBRL Document)\n\n \n\n**\nCertain schedules and exhibits to the Merger Agreement have been omitted pursuant to Item 601(a)(5) of Regulation S-K. The registrant\nhereby undertakes to furnish supplementally a copy of any omitted schedule or exhibit to the U.S. Securities and Exchange Commission\nupon request.*\n\n**\n\n* *\n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant\nto the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by\nthe undersigned hereunto duly authorized.\n\n \n\nDate:\nJuly 2, 2026\nLIXTE\nBIOTECHNOLOGY HOLDINGS, INC.\n\n \n(Registrant)\n\n \n \n \n\n \n*By:*\n*/s/\nGeordan Pursglove*\n\n \n \nGeordan\nPursglove\n\n \n \nPresident\nand Chief Executive Officer"}